MannKind | MNKD - 판매 및 관리 비용





판매 및 관리 비용 변화 날짜
Adma Biologics USD 26.74M 5K 2026-06
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Eli Lilly USD 3.12B 305M 2026-09
Halozyme Therapeutics USD 58.24M 1.24M 2026-09
Insmed USD 253.03M 5.56M 2026-09
Karyopharm Therapeutics USD 10.42M 861K 2026-03
MacroGenics USD 7.9M 1.81M 2026-06
MannKind USD 61.41M 3.11M 2026-09
Merck USD 2.86B 25M 2026-09
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Novavax USD 25.53M 1.34M 2025-12
Novo Nordisk DKK 2.54B 10.68B 2026-06
Pfizer USD 3.28B 132M 2026-09
Sanofi EUR 2.31B 325M 2026-09
Xencor USD 71.93M 5.61M 2026-09